'Game-Changer' For Ardelyx As Tenapanor Phase III Is A Hit In IBS-C
Positive data for its irritable bowel syndrome therapy put Ardelyx in a better position for partnering and set it up for a filing next year.
You may also be interested in...
Tenapanor approved for IBS-C as Ibsrela, but Ardelyx is still seeking a commercial partner for that indication – and is maintaining focus on same molecule in hyperphosphatemia.
The latest drug development news and highlights from our US FDA Performance Tracker.
Ardelyx touts tenapanor's novel mechanism, favorable safety profile; advisory committee announcement reveals US Worldmeds’ bid to revive Novartis’ withdrawn Zelnorm.